- 全部删除
您的购物车当前为空
Azelaoyl PAF是一种强效的PPARγ激动剂,能够竞争性地结合噻唑烷二酮类药物,与罗格列酮(rosiglitazone)的效力相当。在动脉粥样硬化研究中,Azelaoyl PAF通过上调CD36的表达,促进巨噬细胞对氧化低密度脂蛋白(oxLDL)的摄取。在Friedreich's ataxia(FRDA)患者的成纤维细胞中,Azelaoyl PAF显著提高了铁蛋白的mRNA和蛋白质水平。

Azelaoyl PAF是一种强效的PPARγ激动剂,能够竞争性地结合噻唑烷二酮类药物,与罗格列酮(rosiglitazone)的效力相当。在动脉粥样硬化研究中,Azelaoyl PAF通过上调CD36的表达,促进巨噬细胞对氧化低密度脂蛋白(oxLDL)的摄取。在Friedreich's ataxia(FRDA)患者的成纤维细胞中,Azelaoyl PAF显著提高了铁蛋白的mRNA和蛋白质水平。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 500 μg | ¥ 1,370 | 35日内发货 | |
| 1 mg | ¥ 2,490 | 35日内发货 | |
| 5 mg | ¥ 9,860 | 35日内发货 | |
| 10 mg | ¥ 17,900 | 35日内发货 |
Azelaoyl PAF 相关产品
| 产品描述 | Azelaoyl PAF is a potent PPARγ agonist that competitively binds thiazolidinediones with potency comparable to rosiglitazone. In atherosclerosis studies, Azelaoyl PAF promotes the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages by upregulating CD36 expression. In fibroblasts from Friedreich's ataxia (FRDA) patients, Azelaoyl PAF significantly increased mRNA and protein levels of ferritin. |
| 体外活性 | 方法:PPAR-γ 激动剂 Azelaoyl PAF 处理了 Friedreich 共济失调 (FRDA) 患者和健康对照者皮肤活检的人神经母细胞瘤细胞 SKNBE 和原代成纤维细胞。 |
| 别名 | 1-Hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine |
| 分子量 | 651.85 |
| 分子式 | C33H66NO9P |
| CAS No. | 354583-69-0 |
| Smiles | [C@@H](COP(OCC[N+](C)(C)C)(=O)[O-])(OC(CCCCCCCC(O)=O)=O)COCCCCCCCCCCCCCCCC |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||
| 溶解度信息 | Ethanol: 10.00 mg/mL (15.34 mM), Sonication is recommended. PBS (pH 7.2): 6.00 mg/mL (9.20 mM), Sonication is recommended. DMSO: 6.00 mg/mL (9.20 mM), Sonication is recommended. DMF: 20.00 mg/mL (30.68 mM), Sonication is recommended. | |||||||||||||||
溶液配制表 | ||||||||||||||||
PBS (pH 7.2)/DMSO/Ethanol/DMF
| ||||||||||||||||
评论内容